Synonym
Roxatidine Free Base; Desacetyl-tzu-0460
IUPAC/Chemical Name
Acetamide, 2-hydroxy-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-
InChi Key
BCCREUFCSIMJFS-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H26N2O3/c20-14-17(21)18-8-5-11-22-16-7-4-6-15(12-16)13-19-9-2-1-3-10-19/h4,6-7,12,20H,1-3,5,8-11,13-14H2,(H,18,21)
SMILES Code
O=C(NCCCOC1=CC=CC(CN2CCCCC2)=C1)CO
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
306.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ze R, Wang S, Xie M, Zhang B, Tang X, Li J. Roxatidine Attenuates Degradation of Extracellular Matrix. Biomed Pharmacother. 2017 Nov;95:1156-1160. doi: 10.1016/j.biopha.2017.08.130. Epub 2017 Sep 15. PMID: 28926925.
2: Ji L, Wang T, Tian L, Song H, Gao M. Roxatidine inhibits fibrosis by inhibiting NF‑κB and MAPK signaling in macrophages sensing breast implant surface materials. Mol Med Rep. 2020 Jan;21(1):161-172. doi: 10.3892/mmr.2019.10815. Epub 2019 Nov 12. PMID: 31746427; PMCID: PMC6896367.
3: Lee M, Lee NY, Chung KS, Cheon SY, Lee KT, An HJ. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation. Sci Rep. 2017 Jan 31;7:41721. doi: 10.1038/srep41721. PMID: 28139747; PMCID: PMC5282503.
4: Murdoch D, McTavish D. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs. 1991 Aug;42(2):240-60. doi: 10.2165/00003495-199142020-00006. PMID: 1717223.
5: Dammann HG, de Looze SM, Bender W, Labs R. Clinical characteristics of roxatidine acetate: a review. Scand J Gastroenterol Suppl. 1988;146:121-34. doi: 10.3109/00365528809099138. PMID: 2906456.
6: Scholtholt J, Bickel M, Herling AW. A review of the animal pharmacology of roxatidine acetate. Drugs. 1988;35 Suppl 3:30-40. doi: 10.2165/00003495-198800353-00008. PMID: 2905247.
7: Habibullah CM, Habeeb MA, Singh SP. Roxatidine in duodenal ulcer. J Postgrad Med. 1995 Jul-Sep;41(3):64-5. PMID: 10707717.
8: Agrawal SS, Alvin Jose M. Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence. Syst Biol Reprod Med. 2010 Aug;56(4):286-91. doi: 10.3109/19396368.2010.496894. PMID: 20718616.
9: Cho EJ, An HJ, Shin JS, Choi HE, Ko J, Cho YW, Kim HM, Choi JH, Lee KT. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59. doi: 10.1002/jcb.23294. PMID: 21809375.
10: Fock KM, Kang JY, Ng HS, Ng TM, Gwee KA, Lim CC. Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore. J Gastroenterol Hepatol. 1995 Jul- Aug;10(4):379-82. doi: 10.1111/j.1440-1746.1995.tb01587.x. PMID: 8527701.
